French advances to better heal women

Triple negative breast cancer represents 15% of breast cancers (9,000 new cases per year) but remains one of the most difficult to treat due to the resistance of many patients to standard hormonal treatments, including new targeted hormonal therapies. For good reason, the tumor cells of this cancer express neither the hormone receptors (estrogen and progesterone) nor the HER 2 receptor, regulating cell multiplication, present in most breast cancers. This is why considerable research efforts are devoted to it, in the hope of improving the care of these patients, whose treatment options are limited. In recent years, the Institut Curie has mobilized on different fronts to expand the therapeutic offer and detect relapses early. Several trials in progress, presented this week at the largest world cancer congress, organized each year in Chicago by the American Society of Oncology…